Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843194 | 1.00 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL11574607 | 0.89 | KMT2A (0.53) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| Fumaric Acid SCHEMBL2403762 | 0.86 | KMT2A (0.56) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| Fumaric Acid SCHEMBL2710819 | 0.86 | KMT2A (0.56) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL30885716 | 0.85 | KMT2A (0.50) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL3007964 | 0.84 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL19122497 | 0.82 | KMT2A (0.66) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL2103706 | 0.82 | KMT2A (0.64) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL2815639 | 0.82 | KMT2A (0.64) | KMT2AMEN1L3MBTL1TSHRMAPK1 | |
| SCHEMBL2103705 | 0.82 | KMT2A (0.64) | KMT2AMEN1L3MBTL1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204359-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2017-08-16 | — | — | EP | claimed |
| CN-107001278-A | Tetrahydro isoquinoline derivative | UCB生物制药私人有限公司 | 2017-08-01 | — | — | CN | claimed |
| WO-2016055479-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-04-14 | — | — | WO | claimed |
| WO-2014160177-A2 | QUINAZOLINE INHIBITORS OF PI3K | EXELIXIS, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| CN-102203067-B | Hedgehog pathway modulators | IRM LLC | 2014-01-15 | — | — | CN | claimed |
| EP-2556064-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-02-13 | — | — | EP | claimed |
| EP-2542530-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2013-01-09 | — | — | EP | claimed |
| CN-102803247-A | Novel fumarate salts of a histamine H3 receptor antagonist | SANOFI AVENTIS | 2012-11-28 | — | — | CN | claimed |
| CN-102203067-A | Hedgehog pathway modulators | IRM LLC | 2011-09-28 | — | — | CN | claimed |
| WO-2011109680-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2011-09-09 | — | — | WO | claimed |
| WO-2011109675-A2 | PROCESS FOR THE PREPARATION OF 2-(CYCLOHEXYLMETHYL)-N-{2- [(2S)-1-METHYLPYRROLIDIN-2-YL]ETHYL}-1, 2, 3, 4- TETRAHYDROISOQUINOLINE-7-SULFONAMIDE | SANOFI (FR) | 2011-09-09 | — | — | WO | claimed |
| CN-1956962-A | Tetrahydroisoquinoline sulfonamide derivatives, their preparation and their use in therapy | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | CN | claimed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023109909-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2003070244-A1 | ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | KMT2A 2619/4885MEN1 1307/4885L3MBTL1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.